FDA Approves Immunotherapy Keytruda for PD-L1+ TNBC

Options
Moderators
Moderators Member Posts: 25,912
edited November 2020 in Stage IV/Metastatic Breast Cancer, Open to All To Contribute

FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer
November 13, 2020
On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer. Read more...

· Share on FacebookShare on Twitter

Categories